Results 201 to 210 of about 397,641 (267)

What Do We Know About Hypertrophic Cardiomyopathy in Poland in the Period 2016-2021 Based on Data From the Public Health System? [PDF]

Int J Public Health
Niemiec M, Stec M, Grzybowski J, Cegłowska U, Wiśniewska A, Hałgas K, Czepczor K, Podolski M, Gruchlik B, Orzeł-Łomozik G, Cieśla D, Gąsior M, Hryniewiecki T, Leszek P, Caforio ALP, Mizia-Stec K.   +15 more
europepmc   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Intraoperative Cardiac Arrest During Anterior Cervical Discectomy and Fusion Due to Takotsubo Cardiomyopathy: A Case Report. [PDF]

Cureus
Patel V, Litinski A, Rajaram S, Akl K.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Recurrent Ventricular Tachycardia in a Young Adult-Imaging and Genetic Evidence of <i>DSP</i>-Associated Arrhythmogenic Cardiomyopathy: A Case Report. [PDF]

Case Rep Cardiol
Gomez LE, Martinenghi N, Ortiz-Genga M, Tejeira MS, Buonfiglio P, Atamañuk AN.   +5 more
europepmc   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Monomorphic Ventricular Arrhythmias in Athletes

Arrhythmia & Electrophysiology Review, 2019
Jeffrey J Hsu, Ali Nsair, Jamil A Aboulhosn, Tamara B Horwich, Ravi H Dave, Kevin M Shannon, Noel G Boyle, Kalyanam Shivkumar, Jason S Bradfield   +8 more
doaj   +1 more source

2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias [PDF]

, 2019
Cuculich, Phillip, et al,
core   +1 more source